| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,730,000 |
| Market
Cap: |
320.84(M) |
| Last
Volume: |
790,925 |
Avg
Vol: |
788,766 |
| 52
Week Range: |
$1 - $3.58 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 629 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Lexicon Pharmaceuticals is a biopharmaceutical company. Co. discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Co. is also developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. In addition, Co. is conducting preclinical research and development and preparing to conduct clinical development of compounds from several additional drug programs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
29,171,050 |
48,900,910 |
| Total Buy Value |
$0 |
$0 |
$73,835,385 |
$123,160,035 |
| Total People Bought |
0 |
0 |
6 |
6 |
| Total Buy Transactions |
0 |
0 |
14 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Swain Judith L |
Director |
• • – |
2013-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
10,101 |
21,865 |
|
- |
|
| Nies Alan S |
Director |
• • – |
2013-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
10,101 |
26,865 |
|
- |
|
| Palantoni Frank |
Director |
• • – |
2013-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
10,101 |
21,865 |
|
- |
|
| Lapuerta Pablo |
EVP, Clin Dev and CMO |
• • – |
2013-02-28 |
4 |
D |
$1.98 |
$9,356 |
D/D |
(4,725) |
8,275 |
|
- |
|
| Lapuerta Pablo |
EVP, Clin Dev and CMO |
• • – |
2013-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
13,000 |
|
- |
|
| Tessmer James F |
VP, Finance & Accounting |
• • – |
2013-02-28 |
4 |
D |
$1.98 |
$7,538 |
D/D |
(3,807) |
48,003 |
|
- |
|
| Tessmer James F |
VP, Finance & Accounting |
• • – |
2013-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,250 |
51,810 |
|
- |
|
| Wade Jeffrey L |
EVP, Corp Dev and CFO |
• • – |
2013-02-28 |
4 |
D |
$1.98 |
$20,713 |
D/D |
(10,461) |
110,836 |
|
- |
|
| Wade Jeffrey L |
EVP, Corp Dev and CFO |
• • – |
2013-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,250 |
121,297 |
|
- |
|
| Main Alan J |
EVP, Pharmaceutical Research |
• • – |
2013-02-28 |
4 |
D |
$1.98 |
$24,893 |
D/D |
(12,572) |
114,768 |
|
- |
|
| Main Alan J |
EVP, Pharmaceutical Research |
• • – |
2013-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,750 |
127,340 |
|
- |
|
| Sands Arthur T |
President & CEO |
• • – |
2013-02-28 |
4 |
D |
$1.98 |
$39,667 |
D/D |
(20,034) |
942,870 |
|
- |
|
| Sands Arthur T |
President & CEO |
• • – |
2013-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
73,250 |
962,904 |
|
- |
|
| Zambrowicz Brian P |
EVP, Chief Scientific Officer |
• • – |
2013-02-28 |
4 |
D |
$1.98 |
$23,150 |
D/D |
(11,692) |
234,139 |
|
- |
|
| Zambrowicz Brian P |
EVP, Chief Scientific Officer |
• • – |
2013-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
42,750 |
245,831 |
|
- |
|
| Wade Jeffrey L |
EVP, Corp Dev and CFO |
• • – |
2013-01-31 |
4 |
D |
$2.11 |
$21,769 |
D/D |
(10,317) |
83,047 |
|
- |
|
| Wade Jeffrey L |
EVP, Corp Dev and CFO |
• • – |
2013-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,600 |
93,364 |
|
- |
|
| Zambrowicz Brian P |
EVP, Chief Scientific Officer |
• • – |
2013-01-31 |
4 |
D |
$2.11 |
$28,483 |
D/D |
(13,499) |
203,081 |
|
- |
|
| Zambrowicz Brian P |
EVP, Chief Scientific Officer |
• • – |
2013-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
42,100 |
216,580 |
|
- |
|
| Sands Arthur T |
President & CEO |
• • – |
2013-01-31 |
4 |
D |
$2.11 |
$45,226 |
D/D |
(21,434) |
889,654 |
|
- |
|
| Sands Arthur T |
President & CEO |
• • – |
2013-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
73,700 |
911,088 |
|
- |
|
| Tessmer James F |
VP, Finance & Accounting |
• • – |
2013-01-31 |
4 |
D |
$2.11 |
$9,094 |
D/D |
(4,310) |
37,560 |
|
- |
|
| Tessmer James F |
VP, Finance & Accounting |
• • – |
2013-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,200 |
41,870 |
|
- |
|
| Main Alan J |
EVP, Pharmaceutical Research |
• • – |
2013-01-31 |
4 |
D |
$2.11 |
$26,453 |
D/D |
(12,537) |
93,590 |
|
- |
|
| Main Alan J |
EVP, Pharmaceutical Research |
• • – |
2013-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,600 |
106,127 |
|
- |
|
447 Records found
|
|
Page 14 of 18 |
|
|
